<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230826020923&amp;utm_source=Chrome&amp;fc=2023070811404 7&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;ff=20230826020923&amp;utm_source=Chrome&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 26 日星期六 06:09:24 +0000</lastbuilddate><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>冷冻消融与射频消融后心房颤动的进展：CIRCA-DOSE 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>结论：使用射频能量导管消融阵发性房颤与随访时发生持续性房颤的患者较少有关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad572。doi：10.1093/eurheartj/ehad572。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：心房颤动 (AF) 是一种慢性、进展性疾病。持续存在的 AF 与血栓栓塞、心力衰竭和死亡率增加相关。导管消融改变了 AF 进展的致病机制。消融能量对进展为持续性房性快速心律失常。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：纳入 346 名药物难治性阵发性 AF 患者，并随机接受接触力引导射频消融（CF-RF 消融，n = 115）、4 分钟冷冻球囊消融（CRYO-4，n = 115）或 2-分钟冷冻球囊消融（CRYO-2，n = 116）。在研究开始时放置的植入式心脏监测器用于随访。主要结果是持续性房性心律失常的首次发作。次要结果包括房性快速心律失常复发和心律失常负担植入式监视器。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：中位时间为 944.0（四分位距 [IQR]，612.5-1104）天时，115 名患者中有 0 名 (0.0%) 被随机分配至 CF-RF，115 名患者中有 8 名 (7.0%) 被分配至 CRYO-4，并且分配至 CRYO-2 的 116 名患者中，有 5 名 (4.3%) 经历过持续性房性快速心律失常发作 (P = 0.03)。记录显示，在随机分组的患者中，56.5%、53.9% 和 62.9% 的患者出现≥30 秒的房性快速性心律失常复发。分别与 CF-RF、CRYO-4 和 CRYO-2 相比（P = 0.65）。与消融前监测期相比，CF-AF 负担中位数减少了 99.5%（IQR 94.0-100.0%）。 RF，CRYO-4 为 99.9% (IQR 93.3-100.0%)，CRYO-2 为 99.1% (IQR 87.0-100.0%) (P = 0.38)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：使用射频能量导管消融阵发性房颤与随访时发生持续性房颤的患者较少有关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37624879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37624879</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad572>10.1093/eurheartj/ehad572</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37624879</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——贾森·G·安德拉德</dc:creator><dc:creator>——马克·W·德耶尔</dc:creator><dc:creator>保罗·凯里</dc:creator><dc:creator>让·香槟</dc:creator><dc:creator>梁薛彼得</dc:creator><dc:creator>保罗·诺瓦克</dc:creator><dc:creator>劳伦斯·斯特恩斯</dc:creator><dc:creator>让-弗朗索瓦·鲁</dc:creator><dc:creator>约翰·萨普</dc:creator><dc:creator>理查德·贝内特</dc:creator><dc:creator>马修·贝内特</dc:creator><dc:creator>——纳撒尼尔·霍金斯</dc:creator><dc:creator>普拉山坦·桑德斯</dc:creator><dc:creator>洛朗·麦克尔</dc:creator><dc:creator>CIRCA-DOSE 研究人员</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>冷冻消融与射频消融后心房颤动的进展：CIRCA-DOSE 试验</dc:title><dc:identifier>下午：37624879</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad572</dc:identifier></item><item><title>严重三尖瓣反流患者的 TRI-SCORE 和干预获益</title><link/>https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>结论：无论采用何种治疗方式，生存率都会随着 TRI-SCORE 的增加而逐渐降低。与保守治疗相比，早期成功的手术或经导管干预可改善低 TRI-SCORE 和中等程度 TRI-SCORE 患者的 2 年生存率，而在高 TRI-SCORE 类别中没有观察到任何好处。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad585。doi：10.1093/eurheartj/ehad585。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：三尖瓣反流 (TR) 矫正的益处和干预时机尚不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：TRIGISTRY 纳入了 2,413 例严重孤立性功能性 TR 患者（1217 例进行保守治疗，551 例进行孤立性三尖瓣手术，645 例进行经导管瓣膜修复）。主要终点是 2 年生存率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：32%的患者TRI-SCORE为低（≤3），33%为中（4-5），35%为高（≥6），97%和65%的患者获得了成功矫正。三个治疗组的生存率随着 TRI-SCORE 的增加而降低（所有 P &lt; 0.0001）。在低 TRI-SCORE 类别中，手术组和经导管组的生存率高于保守治疗组（93%, 87分别为 % 和 79%；P = 0.0002）。在中间类别中，总体上观察到组间没有显着差异（分别为 80%、71% 和 71%；P = 0.13），但是当分析仅限于成功矫正的患者（分别为 80%、81% 和 71%；P = 0.009）。在高 TRI-SCORE 类别中，即使仅限于成功矫正的患者（61%、分别为 68% 和 58%，P = 0.08）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：无论采用何种治疗方式，生存率都会随着 TRI-SCORE 的增加而逐渐降低。与保守治疗相比，早期成功的手术或经导管干预可改善低 TRI-SCORE 和中等程度 TRI-SCORE 患者的 2 年生存率，而在高 TRI-SCORE 类别中没有观察到任何好处。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37624856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37624856</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad585>10.1093/eurheartj/ehad585</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37624856</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>朱利安·德雷福斯</dc:creator><dc:creator>泽维尔·加卢</dc:creator><dc:creator>毛里齐奥·塔拉马索</dc:creator><dc:creator>格雷戈尔·海辛格</dc:creator><dc:creator>乔瓦尼·本法里</dc:creator><dc:creator>卡尔-帕特里克·克雷索亚</dc:creator><dc:creator>费尔南多·华雷斯·卡索</dc:creator><dc:creator>哈齐姆·奥姆兰</dc:creator><dc:creator>约翰·博博特</dc:creator><dc:creator>克里斯托·伊利亚迪斯</dc:creator><dc:creator>朱利奥·鲁索</dc:creator><dc:creator>严·托皮尔斯基</dc:creator><dc:creator>马塞尔·韦伯</dc:creator><dc:creator>路易斯·农贝拉-弗朗哥</dc:creator><dc:creator>亚历山德拉·萨拉</dc:creator><dc:creator>安德里亚·埃克塞雷斯-埃斯特夫</dc:creator><dc:creator>翁伯纳德</dc:creator><dc:creator>让-弗朗索瓦·奥巴迪亚</dc:creator><dc:creator>罗德里戈·埃斯特维兹·洛雷罗</dc:creator><dc:creator>伊丽莎白·瑞安特</dc:creator><dc:creator>埃尔万·多纳尔</dc:creator><dc:creator>约尔格·豪斯莱特</dc:creator><dc:creator>路易吉·巴达诺</dc:creator><dc:creator>蒂埃里·勒图尔诺</dc:creator><dc:creator>奥古斯丁·科瓦纳</dc:creator><dc:creator>托马斯·莫迪恩</dc:creator><dc:creator>阿齐姆·拉提卜</dc:creator><dc:creator>法比安·普拉兹</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>何塞·路易斯·萨莫拉诺</dc:creator><dc:creator>拉尔夫·斯蒂芬·冯·巴德莱本</dc:creator><dc:creator>吉尔伯特·HL·唐</dc:creator><dc:creator>丽贝卡·哈恩</dc:creator><dc:creator>约翰·韦伯</dc:creator><dc:creator>德尼萨·穆拉鲁</dc:creator><dc:creator>穆罕默德·内贾里</dc:creator><dc:creator>陈文森</dc:creator><dc:creator>米歇尔·德博尼斯</dc:creator><dc:creator>曼努埃尔·卡内罗-阿尔卡扎</dc:creator><dc:creator>格奥尔格·尼克尼格</dc:creator><dc:creator>罗曼·菲斯特</dc:creator><dc:creator>克里斯托夫·特里布依洛</dc:creator><dc:creator>沃尔克·鲁道夫</dc:creator><dc:creator>胡安·克雷斯塔内洛</dc:creator><dc:creator>菲利普·鲁兹</dc:creator><dc:creator>菲利普·巴尔特科</dc:creator><dc:creator>弗朗西斯科·麦萨诺</dc:creator><dc:creator>杰伦·巴克斯</dc:creator><dc:creator>莫里斯·恩里克斯·萨拉诺</dc:creator><dc:creator>大卫·梅西卡-泽图恩</dc:creator><dc:creator>TRIGISTRY调查员</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>严重三尖瓣反流患者的 TRI-SCORE 和干预获益</dc:title><dc:identifier>下午：37624856</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad585</dc:identifier></item><item><title>房颤患者的不良后果：以往的成功如何揭示新的挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad575。doi：10.1093/eurheartj/ehad575。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37624615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37624615</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad575>10.1093/eurheartj/ehad575</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37624615</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>帕斯卡·B·迈尔</dc:creator><dc:creator>大卫·科南</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>房颤患者的不良后果：以往的成功如何揭示新的挑战</dc:title><dc:identifier>下午：37624615</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad575</dc:identifier></item><item><title>房颤诊断后特定原因死亡率的时间趋势</title><link/>https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>结论：房颤诊断后，心脑血管死亡率和住院率下降，而非心脑血管疾病住院率上升。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad571。doi：10.1093/eurheartj/ehad571。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：关于心房颤动（AF）诊断后的结果的报告是相互矛盾的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从 2001 年 1 月 1 日至 2017 年 12 月 31 日的英国临床实践研究 Datalink-GOLD 数据集中确定首次诊断 AF 的年龄≥16 岁的个体。主要结局是全因死亡率和特定原因死亡率和住院治疗诊断后 1 年。使用泊松回归计算死亡率比率 (RR) 和住院发病率比率 (IRR) 以及比较 2001/02 和 2016/17 的 95% 置信区间 (CI)，并根据年龄进行调整，性别、地区、社会经济地位和 18 种主要合并症。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 72 412 名参与者中，平均 (SD) 年龄为 75.6 (12.4) 岁，44 762 名 (61.8%) 患有 ≥3 种合并症。全因死亡率下降（RR 2016/17 vs 2001/02 0.72；95% CI 0.65 ）-0.80），心血管死亡率（RR 0.46；95% CI 0.37-0.58）和脑血管死亡率（RR 0.41；95% CI 0.29-0.60）大幅下降，但非心/脑血管死亡原因则没有大幅下降（RR 0.91；95% CI 0.29-0.60）。 95 % CI 0.80–1.04)。到 2016/17 年，痴呆症死亡人数 (67, 8.0%)，超过急性心肌梗塞、心力衰竭和急性中风死亡人数的总和 (56, 6.7%, p &lt; 0.001)。IRR 2016/17与 2001/2002 1.17；95% CI，1.13-1.22）相比，特别是非心脑血管原因（IRR 1.42；95% CI 1.39-1.45）。年龄较大、贫困程度较高和医院诊断的 AF 患者事件发生率较高。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：房颤诊断后，心脑血管死亡率和住院率下降，而非心脑血管疾病住院率上升。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37624589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37624589</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad571>10.1093/eurheartj/ehad571</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37624589</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>吴建华</dc:creator><dc:creator>拉梅什·纳达拉贾</dc:creator><dc:creator>中尾洋子</dc:creator><dc:creator>中尾一宏</dc:creator><dc:creator>——克里斯·威尔金森</dc:creator><dc:creator>——J·坎贝尔·考恩</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>克里斯·P·盖尔</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>房颤诊断后特定原因死亡率的时间趋势</dc:title><dc:identifier>下午：37624589</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad571</dc:identifier></item><item><title>可生物降解聚合物或耐用聚合物支架用于高出血风险患者：一项随机、开放标签临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37624364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 25 日。doi：10.1161/CIRCULATIONAHA.123.065448。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37624364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37624364</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065448>10.1161/CIRCULATIONAHA.123.065448</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37624364</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>马可·瓦尔吉米利</dc:creator><dc:creator>阿德里安·沃达恰克</dc:creator><dc:creator>拉尔夫·托尔格</dc:creator><dc:creator>贝拉·默克利</dc:creator><dc:creator>亨宁·凯尔贝克</dc:creator><dc:creator>——雅采克·勒古特科</dc:creator><dc:creator>斯特凡诺·加利</dc:creator><dc:creator>马蒂厄·戈丁</dc:creator><dc:creator>加博·G·托特</dc:creator><dc:creator>蒂博·勒穆西耶</dc:creator><dc:creator>本杰明·洪顿</dc:creator><dc:creator>彼得·劳伦兹·迪特里希</dc:creator><dc:creator>弗朗西斯·斯塔门</dc:creator><dc:creator>伯特·斐迪南</dc:creator><dc:creator>约翰·西尔万</dc:creator><dc:creator>达维德·卡波丹诺</dc:creator><dc:creator>纪尧姆·凯拉</dc:creator><dc:creator>Bioflow-DAPT 研究人员</dc:creator><dc:date>2023-08-25</dc:date><dc:source>循环</dc:source><dc:title>可生物降解聚合物或耐用聚合物支架用于高出血风险患者：一项随机、开放标签临床试验</dc:title><dc:identifier>下午：37624364</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065448</dc:identifier></item><item><title>乙酰唑胺治疗急性心力衰竭：ADVOR 是一个谜团吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37623429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad560。doi：10.1093/eurheartj/ehad560。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37623429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37623429</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad560>10.1093/eurheartj/ehad560</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37623429</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>赫克托·布埃诺</dc:creator><dc:creator>米尔顿·帕克</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>乙酰唑胺治疗急性心力衰竭：ADVOR 是一个谜团吗？</dc:title><dc:identifier>下午：37623429</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad560</dc:identifier></item><item><title>乙酰唑胺治疗急性失代偿性心力衰竭的肾功能和减充血：ADVOR 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37623428/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>结论：乙酰唑胺与整个肾功能范围内充血成功率较高相关，对于 eGFR 较低的患者，钠尿和利尿效果更显着。虽然乙酰唑胺更容易发生 WRF，但这与不良临床结果无关.. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad557。doi：10.1093/eurheartj/ehad557。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：在 ADVOR 试验中，乙酰唑胺改善了急性失代偿性心力衰竭 (ADHF) 的充血缓解作用。乙酰唑胺的有益作用在整个肾功能范围内是否一致仍不清楚。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这是对 ADVOR 试验的预先设定分析，该试验将 519 名 ADHF 患者随机分配至静脉注射乙酰唑胺或匹配的安慰剂，并联合静脉袢利尿剂。根据基线肾功能评估减充血、利尿、排尿钠和临床结果的主要终点。评估治疗组之间肾功能的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入院时，中位估计肾小球滤过率 (eGFR) 为 40 (30-52) mL/min/1.73 m²。乙酰唑胺持续增加整个 eGFR 范围内充血缓解的可能性（p 交互作用 = 0.977）。总体而言，乙酰唑胺的尿钠排泄和利尿作用较高，对于低 eGFR 患者（均 p 交互作用 &lt;0.007）在治疗期间的治疗效果较高（40.5% vs. 18.9%；p&lt;0.001），但没有差异3 个月后肌酐水平升高 (p=0.565)。这与较高的心力衰竭住院率和死亡率无关（p 然而，出院时充血缓解与较低的不良临床结果发生率相关，无论 WRF 是否发生（p -交互作用=0.805）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：乙酰唑胺与整个肾功能范围内充血成功率较高相关，对于 eGFR 较低的患者，钠尿和利尿效果更显着。虽然乙酰唑胺更容易发生 WRF，但这与不良临床结果无关.. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">临床试验.GOV 标识符：NCT03505788。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37623428/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37623428</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad557>10.1093/eurheartj/ehad557</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37623428</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>伊芙琳·米克斯</dc:creator><dc:creator>杰罗恩·道</dc:creator><dc:creator>彼得·马滕斯</dc:creator><dc:creator>塞巴斯蒂安·德霍特</dc:creator><dc:creator>弗雷德里克·H·韦尔布鲁格</dc:creator><dc:creator>佩特拉·尼斯特更多</dc:creator><dc:creator>乔津·M·特尔·马腾</dc:creator><dc:creator>——凯文·达曼</dc:creator><dc:creator>亚历山大·梅巴扎</dc:creator><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>弗兰克·鲁斯奇卡</dc:creator><dc:creator>WH 邓伟逊</dc:creator><dc:creator>马蒂亚斯·杜邦</dc:creator><dc:creator>威尔弗里德·穆伦斯</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>乙酰唑胺治疗急性失代偿性心力衰竭的肾功能和减充血：ADVOR 试验</dc:title><dc:identifier>下午：37623428</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad557</dc:identifier></item><item><title> 2021年ESC急慢性心力衰竭诊治指南2023年重点更新</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad195。doi：10.1093/eurheartj/ehad195。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622666</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad195>10.1093/eurheartj/ehad195</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622666</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>特里萨·麦克唐纳</dc:creator><dc:creator>Marco Metra更多</dc:creator><dc:creator>玛丽安娜·阿达莫</dc:creator><dc:creator>——罗伊·S·加德纳</dc:creator><dc:creator>安德烈亚斯·鲍姆巴赫</dc:creator><dc:creator>迈克尔·伯姆</dc:creator><dc:creator>哈兰·布里</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>耶莱娜·塞卢特基​​内</dc:creator><dc:creator>奥维迪乌·奇翁塞尔</dc:creator><dc:creator>约翰·GF·克莱兰</dc:creator><dc:creator>玛丽亚·杰内罗萨·克雷斯波-莱罗</dc:creator><dc:creator>迪米特里奥斯·法马基斯</dc:creator><dc:creator>马丁·吉拉德</dc:creator><dc:creator>斯蒂芬·海曼斯</dc:creator><dc:creator>阿诺·W·锄头</dc:creator><dc:creator>小贾斯玛</dc:creator><dc:creator>埃娃·扬科斯卡</dc:creator><dc:creator>米贾·兰斯卡克</dc:creator><dc:creator>卡罗琳·SP·林</dc:creator><dc:creator>亚历山大·里昂</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>亚历山大·梅巴扎</dc:creator><dc:creator>——理查德·明德姆</dc:creator><dc:creator>克劳迪奥·穆内雷托</dc:creator><dc:creator>马西莫·弗朗切斯科·皮波利</dc:creator><dc:creator>苏珊娜·普赖斯</dc:creator><dc:creator>朱塞佩·MC·罗萨诺</dc:creator><dc:creator>弗兰克·鲁斯奇卡</dc:creator><dc:creator>安妮·凯瑟琳·斯基贝隆德</dc:creator><dc:creator>ESC 科学文献组</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2021年ESC急慢性心力衰竭诊治指南2023年重点更新</dc:title><dc:identifier>下午：37622666</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad195</dc:identifier></item><item><title> 2023 ESC 糖尿病患者心血管疾病管理指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622663/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad192。doi：10.1093/eurheartj/ehad192。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622663/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622663</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad192>10.1093/eurheartj/ehad192</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622663</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>尼古拉斯·马克思</dc:creator><dc:creator>马西莫·费德里奇</dc:creator><dc:creator>卡塔琳娜·舒特</dc:creator><dc:creator>德克·穆勒·维兰德</dc:creator><dc:creator>Ramzi A Ajjan更多</dc:creator><dc:creator>曼努埃尔·J·安图内斯</dc:creator><dc:creator>鲁克桑德拉·克里斯托多雷斯库</dc:creator><dc:creator>卡罗琳·克劳福德</dc:creator><dc:creator>埃马努埃莱·迪·安杰兰托尼奥</dc:creator><dc:creator>比约恩·埃利亚松</dc:creator><dc:creator>克里斯汀·埃斯皮诺拉-克莱因</dc:creator><dc:creator>洛朗·福齐尔</dc:creator><dc:creator>马丁·哈勒</dc:creator><dc:creator>——威廉·G·赫林顿</dc:creator><dc:creator>亚历山德拉·考茨基-维勒</dc:creator><dc:creator>叶卡泰里尼·兰布里努</dc:creator><dc:creator>马切伊·莱西亚克</dc:creator><dc:creator>马达莱娜·莱蒂诺</dc:creator><dc:creator>——达伦·K·麦奎尔</dc:creator><dc:creator>威尔弗里德·穆伦斯</dc:creator><dc:creator>比安卡·罗卡</dc:creator><dc:creator>纳维德·萨塔尔</dc:creator><dc:creator>ESC 科学文献组</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2023 ESC 糖尿病患者心血管疾病管理指南</dc:title><dc:identifier>下午：37622663</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad192</dc:identifier></item><item><title>基于能力的心脏成像，用于以患者为中心的护理。</title><link/> https://pubmed.ncbi.nlm.nih.gov/37622660/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>影像学在管理心脏病的各个方面发挥着不可或缺的作用，心脏影像学是心脏病专家的核心能力。欧洲心脏病学会 (ESC) 和 ESC 的欧洲心血管影像协会 (EACVI) 已经开发并实施了成功的教育... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad578。doi：10.1093/eurheartj/ehad578。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">影像学在管理心脏病的各个方面发挥着不可或缺的作用，心脏影像学是心脏病专家的核心能力。欧洲心脏病学会 (ESC) 和 ESC 的欧洲心血管影像协会 (EACVI) 已经开发并针对所有心脏成像模式实施了成功的教育和认证计划。基于心脏成像服务，确保他们在心脏成像的整个过程中得到充分的培训和能力，从临床适应症到选择最佳成像测试来回答临床问题，再到图像采集、分析、解释、存储、存储和结果 该声明强调了基于能力的心脏成像交付的需要，这是最佳、有效和高效的患者护理的关键。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622660/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622660</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad578>10.1093/eurheartj/ehad578</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622660</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——马克·韦斯特伍德</dc:creator><dc:creator>Ana G Almeida更多</dc:creator><dc:creator>埃马努埃莱·巴巴托</dc:creator><dc:creator>维多利亚·德尔加多</dc:creator><dc:creator>圣德莱格罗塔列</dc:creator><dc:creator>凯文·F·福克斯</dc:creator><dc:creator>Luna Gargani更多</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>帕尔·毛罗维奇-霍瓦特</dc:creator><dc:creator>何塞·L·梅里诺</dc:creator><dc:creator>——理查德·明德姆</dc:creator><dc:creator>德尼萨·穆拉鲁</dc:creator><dc:creator>利斯·纽贝克</dc:creator><dc:creator>罗宾·尼维尔特</dc:creator><dc:creator>迈克尔·帕帕达基斯</dc:creator><dc:creator>詹卢卡·庞托内</dc:creator><dc:creator>苏珊娜·普赖斯</dc:creator><dc:creator>朱塞佩·MC·罗萨诺</dc:creator><dc:creator>亚历克西娅·罗西</dc:creator><dc:creator>莱拉·埃利夫·萨德</dc:creator><dc:creator>珍妮特·舒尔茨-门格</dc:creator><dc:creator>弗朗茨·魏丁格</dc:creator><dc:creator>斯蒂芬·阿肯巴赫</dc:creator><dc:creator>史蒂芬·彼得森</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>基于能力的心脏成像，用于以患者为中心的护理。</dc:title><dc:identifier>下午：37622660</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad578</dc:identifier></item><item><title> 2023 年 ESC 心肌病管理指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad194。doi：10.1093/eurheartj/ehad194。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622657</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad194>10.1093/eurheartj/ehad194</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622657</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>埃琳娜·阿贝洛</dc:creator><dc:creator>亚历山德罗斯·普罗托塔里奥斯</dc:creator><dc:creator>胡安·吉梅诺</dc:creator><dc:creator>埃洛伊莎·阿布斯蒂尼</dc:creator><dc:creator>罗伯托·巴里亚莱斯-维拉</dc:creator><dc:creator>克里斯蒂娜·巴索</dc:creator><dc:creator>康妮·R·贝齐纳</dc:creator><dc:creator>埃琳娜·比亚吉尼</dc:creator><dc:creator>尼科·布洛姆</dc:creator><dc:creator>鲁道夫·德波尔</dc:creator><dc:creator>蒂姆·德温特</dc:creator><dc:creator>佩里·埃利奥特</dc:creator><dc:creator>马库斯·弗拉瑟</dc:creator><dc:creator>巴勃罗·加西亚-帕维亚</dc:creator><dc:creator>克里斯蒂娜·H·豪加</dc:creator><dc:creator>朱迪·英格尔斯</dc:creator><dc:creator>鲁克桑德拉·瓦纳·贾克特</dc:creator><dc:creator>萨宾·克拉森</dc:creator><dc:creator>朱塞佩·利蒙格利</dc:creator><dc:creator>巴特·洛伊斯</dc:creator><dc:creator>延斯·摩根森</dc:creator><dc:creator>亚科波·奥利沃托</dc:creator><dc:creator>安东尼斯·潘塔齐斯</dc:creator><dc:creator>桑杰·夏尔马更多</dc:creator><dc:creator>J·彼得·范·廷泰伦</dc:creator><dc:creator>詹姆斯·S·威尔</dc:creator><dc:creator>胡安·巴勃罗·卡斯基</dc:creator><dc:creator>ESC 科学文献组</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2023 年 ESC 心肌病管理指南</dc:title><dc:identifier>下午：37622657</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad194</dc:identifier></item><item><title> 2023 ESC 心内膜炎治疗指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad193。doi：10.1093/eurheartj/ehad193。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622656</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad193>10.1093/eurheartj/ehad193</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622656</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>维多利亚·德尔加多</dc:creator><dc:creator>尼娜·阿杰蒙·马桑</dc:creator><dc:creator>苏珊娜·德·瓦哈</dc:creator><dc:creator>尼古拉斯·博纳罗斯</dc:creator><dc:creator>玛格丽塔·布里达</dc:creator><dc:creator>哈兰·布里</dc:creator><dc:creator>斯特凡诺·卡塞利</dc:creator><dc:creator>托斯顿·多恩斯特</dc:creator><dc:creator>斯蒂芬·埃德希</dc:creator><dc:creator>保拉·安娜·埃尔巴</dc:creator><dc:creator>丹·福达格</dc:creator><dc:creator>埃米尔·L·福斯波尔</dc:creator><dc:creator>扬·科瓦奇</dc:creator><dc:creator>卡洛斯·梅斯特雷斯更多</dc:creator><dc:creator>欧文·米勒</dc:creator><dc:creator>何塞·M·米罗</dc:creator><dc:creator>米哈尔·帕兹德尔尼克</dc:creator><dc:creator>玛丽亚·纳扎雷娜·皮齐</dc:creator><dc:creator>爱德华·金塔纳</dc:creator><dc:creator>特里娜·伯恩霍尔特·拉斯穆森</dc:creator><dc:creator>阿森·D·里斯蒂奇</dc:creator><dc:creator>何塞普·罗德斯·卡包</dc:creator><dc:creator>亚历山德罗·西奥尼斯</dc:creator><dc:creator>莉丝尔·乔安娜·祖尔克</dc:creator><dc:creator>——迈克尔·A·博格</dc:creator><dc:creator>ESC 科学文献组</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2023 ESC 心内膜炎治疗指南</dc:title><dc:identifier>下午：37622656</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad193</dc:identifier></item><item><title> 2023 年 ESC 急性冠状动脉综合征管理指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 25 日：ehad191。doi：10.1093/eurheartj/ehad191。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622654</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad191>10.1093/eurheartj/ehad191</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622654</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——罗伯特·A·伯恩</dc:creator><dc:creator>泽维尔·罗塞洛</dc:creator><dc:creator>JJ Coughlan更多</dc:creator><dc:creator>埃马努埃莱·巴巴托</dc:creator><dc:creator>科林·贝瑞</dc:creator><dc:creator>阿莱德酋长</dc:creator><dc:creator>马克·J·克莱斯</dc:creator><dc:creator>格奥尔基·安德烈·丹</dc:creator><dc:creator>——马克·R·德韦克</dc:creator><dc:creator>玛丽·加尔布雷斯</dc:creator><dc:creator>马丁·吉拉德</dc:creator><dc:creator>琳恩·欣特布赫纳</dc:creator><dc:creator>埃娃·扬科斯卡</dc:creator><dc:creator>彼得·朱尼</dc:creator><dc:creator>木村武</dc:creator><dc:creator>Vijay Kunadian更多</dc:creator><dc:creator>玛格丽特·莱奥斯多蒂尔</dc:creator><dc:creator>罗伯托·洛鲁索</dc:creator><dc:creator>罗伯托·佩德雷蒂</dc:creator><dc:creator>安杰洛斯·G·里戈普洛斯</dc:creator><dc:creator>玛丽亚·鲁比尼·吉梅内斯</dc:creator><dc:creator>霍尔格·蒂勒</dc:creator><dc:creator>帕斯卡·弗兰克斯 (Pascal Vranckx)</dc:creator><dc:creator>斯文·沃斯曼</dc:creator><dc:creator>纳内特·卡斯·温格</dc:creator><dc:creator>Borja Ibanez更多</dc:creator><dc:creator>ESC 科学文献组</dc:creator><dc:date>2023-08-25</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>2023 年 ESC 急性冠状动脉综合征管理指南</dc:title><dc:identifier>下午：37622654</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad191</dc:identifier></item><item><title>短暂性脑缺血发作后缺血性中风的长期发病率：2014-2020 年全国范围内的研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37622531/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>背景：短暂性脑缺血发作（TIA）后缺血性卒中的短期发病率很高。丹麦卒中登记处（2014年1月至2020年12月）中的（索引日期）被纳入，并与背景人群中的个体进行1:4匹配根据年龄、性别和日历年份，对首次缺血性中风患者进行 1:1 的比例。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 25 日。doi：10.1161/CIRCULATIONAHA.123.065446。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景</b><b>：</b>短暂性脑缺血发作（TIA）后缺血性中风的短期发病率很高。丹麦中风登记处（2014年1月至2020年12月）中的（索引日期）被纳入，并与背景人群中的个体进行1:4匹配以及根据年龄、性别和日历年对首次缺血性中风患者进行 1:1 的比例。从索引日期起，缺血性中风的发生率和死亡率分别由 Aalen-Johansen 和 Kaplan-Meier 估计器估计，并在<b>结果：</b>我们纳入了 21,500 名 TIA 患者，其中 86,000 名患者来自背景人群 TIA 患者比背景人群有更多合并症，但比对照卒中人群少。TIA 后缺血性卒中的五年发病率（6.1% [95% CI 5.7-6.5]）高于背景人群（1.5% [95% CI 1.4-1.6]，风险比 (HR) 5.14 [95% CI 4.65-5.69]），但低于背景人群对照卒中人群（8.9% [95%CI 8.4-9.4]，HR 0.58 [95%CI 0.53-0.64]）。TIA 患者的五年死亡率（18.6% [95%CI 17.9] -19.3]）为高于背景人群（14.8% [95% CI 14.5-15.1]，HR 1.26 [95% CI 1.20-1.32]），但低于对照卒中人群（30.1% [95% CI 29.3-30.9），HR 0.41 [95% CI 0.39–0.44]）。<b>结论：</b>首次 TIA 患者在 5 年随访期间缺血性卒中发生率为 6.1%。在调整相关合并症后，该发生率大约高出五倍比背景人群中的对照组低 40%，比复发性缺血性中风患者低 40%。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37622531/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37622531</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065446>10.1161/循环AHA.123.065446</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37622531</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>眼镜蛇恩博格绑定</dc:creator><dc:creator>贾瓦德·H·巴特</dc:creator><dc:creator>玛丽·达姆·劳里森</dc:creator><dc:creator>索伦·隆德·克里斯滕森</dc:creator><dc:creator>索伦·帕斯克·约翰森</dc:creator><dc:creator>约翰娜·克罗尔</dc:creator><dc:creator>彼得·L·格拉弗森</dc:creator><dc:creator>克里斯蒂娜·克鲁斯</dc:creator><dc:creator>克里斯蒂安·托普·佩德森</dc:creator><dc:creator>拉斯·科伯</dc:creator><dc:creator>埃米尔·L·福斯波尔</dc:creator><dc:date>2023-08-25</dc:date><dc:source>循环</dc:source><dc:title>短暂性脑缺血发作后缺血性中风的长期发病率：2014-2020 年全国范围内的研究</dc:title><dc:identifier>下午：37622531</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065446</dc:identifier></item><item><title> DOAC 评分的开发和验证：一种新型出血风险预测工具，适用于使用直接口服抗凝剂的心房颤动患者</title><link/>https://pubmed.ncbi.nlm.nih.gov/37621213/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 25 日。doi：10.1161/CIRCULATIONAHA.123.064556。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37621213/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37621213</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064556>10.1161/CIRCULATIONAHA.123.064556</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37621213</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>拉胡尔·阿加瓦尔</dc:creator><dc:creator>克里斯蒂安·拉夫</dc:creator><dc:creator>萨维里奥·维尔多内</dc:creator><dc:creator>西尔维·佩罗</dc:creator><dc:creator>Ajay K Kakkar更多</dc:creator><dc:creator>迈克尔·G·帕拉佐洛</dc:creator><dc:creator>马克·多莱斯</dc:creator><dc:creator>格洛丽亚·卡亚尼</dc:creator><dc:creator>丹尼尔·E·辛格</dc:creator><dc:creator>埃里克·塞塞姆斯基</dc:creator><dc:creator>乔纳森·皮奇尼</dc:creator><dc:creator>乌斯曼·塔希尔</dc:creator><dc:creator>沉长雨</dc:creator><dc:creator>——罗伯特·W·叶</dc:creator><dc:date>2023-08-25</dc:date><dc:source>循环</dc:source><dc:title>DOAC 评分的开发和验证：一种新型出血风险预测工具，适用于使用直接口服抗凝剂的心房颤动患者</dc:title><dc:identifier>下午：37621213</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064556</dc:identifier></item><item><title> DOAC 分数填补了重要的知识空白</title><link/>https://pubmed.ncbi.nlm.nih.gov/37621202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 25 日。doi：10.1161/CIRCULATIONAHA.123.066316。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37621202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37621202</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066316>10.1161/CIRCULATIONAHA.123.066316</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37621202</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>迈克尔·D·埃泽科维茨</dc:creator><dc:creator>穆罕默德·卡马雷丁</dc:creator><dc:date>2023-08-25</dc:date><dc:source>循环</dc:source><dc:title>DOAC 分数填补了重要的知识空白</dc:title><dc:identifier>下午：37621202</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066316</dc:identifier></item><item><title>心力衰竭患者盲目退出恩格列净或安慰剂长期随机治疗</title><link/>https://pubmed.ncbi.nlm.nih.gov/37621153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 8 月 24 日。doi：10.1161/CIRCULATIONAHA.123.065748。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37621153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37621153</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065748>10.1161/CIRCULATIONAHA.123.065748</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37621153</guid><pubDate> Fri, 25 Aug 2023 06:00:00 -0400</pubDate><dc:creator>米尔顿·帕克</dc:creator><dc:creator>贾维德·巴特勒</dc:creator><dc:creator>科尔杜拉·泽勒</dc:creator><dc:creator>斯图尔特·J·波科克</dc:creator><dc:creator>玛蒂娜·布鲁克曼</dc:creator><dc:creator>若昂·佩德罗·费雷拉</dc:creator><dc:creator>格拉西莫斯·菲利帕托斯</dc:creator><dc:creator>穆罕默德·沙里克·乌斯曼更多</dc:creator><dc:creator>Faiez Zannad更多</dc:creator><dc:creator>斯特凡·D·安克</dc:creator><dc:date>2023-08-25</dc:date><dc:source>循环</dc:source><dc:title>心力衰竭患者盲目退出恩格列净或安慰剂长期随机治疗</dc:title><dc:identifier>下午：37621153</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065748</dc:identifier></item><item><title>根据 2022 年 ESC/ERS 指南，轻度肺动脉高压结果的预测因素：EVIDENCE-PAH 英国研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37619574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230826020923&amp;v=2.17.9.post6+86293ac<description>结论：这项研究支持 ESC/ERS 指南在 PH 人群中诊断类别的变化。新纳入的患者死亡率增加，与严重的肺部或心脏病无关。这个新类别中的大多数患者患有潜在的心脏或肺部疾病疾病而不是孤立的肺血管病。如果存在合并症，死亡率会更高。严格的表型分析对于确定哪些患者有进行性进展的风险至关重要... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 24 日：ehad532。doi：10.1093/eurheartj/ehad532。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：迄今为止完成的肺动脉高压干预研究表明，对于平均肺动脉压（mPAP）（≥25 mmHg）显着升高且肺血管阻力（PVR）>; 3个伍德单位（WU）的有症状患者有效然而，在健康状态下，休息时 mPAP 不超过 20 mmHg，PVR 为 2 WU 或更低。ESC/ERS 指南最近已更新以反映这一点。关于这些新定义人群的性质，已发表的数据有限 ( mPAP 21-24 mmHg 和 PVR >;2-≤3 WU) 以及合并症在确定其自然史中的作用。随着指南的变化，有必要更详细地了解这一人群以及 ESC/ERS 指南的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A retrospective nationwide evaluation of the role of pulmonary haemodynamics and comorbidity in predicting survival among patients referred to the UK pulmonary hypertension (PH) centres between 2009 and 2017. In total, 2929 patients were included in the study. Patients were stratified by mPAP (&lt;21 mmHg, 21-24 mmHg, and ≥25 mmHg) and PVR (≤2 WU, >; 2-≤3 WU, and >;3 WU), with 968 (33.0%) in the mPAP &lt;21 mmHg group, 689 (23.5%) in the mPAP 21-24 mmHg group, and 1272 (43.4%) in the mPAP ≥25 mmHg group. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Survival was negatively correlated with mPAP and PVR in the population as a whole. Survival in patients with mildly elevated mPAP (21-24 mmHg) or PVR (>;2-≤3WU) was lower than among those with normal pressures (mPAP &lt;21 mmHg) and normal PVR (PVR ≤ 2WU) independent of comorbid lung and heart disease [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.14-1.61, P = .0004 for mPAP vs. HR 1.28, 95% CI 1.10-1.49, P = .0012 for PVR]. Among patients with mildly elevated mPAP, a mildly elevated PVR remained an independent predictor of survival when adjusted for comorbid lung and heart disease (HR 1.33, 95% CI 1.01-1.75, P = .042 vs. HR 1.4, 95% CI 1.06-1.86, P = .019). 68.2% of patients with a mPAP 21-24 mmHg had evidence of underlying heart or lung disease. Patients with mildly abnormal haemodynamics were not more symptomatic than patients with normal haemodynamics. Excluding patients with heart and lung disease, connective tissue disease was associated with a poorer survival among those with PH. In this subpopulation evaluating those with a mPAP of 21-24 mmHg, survival curves only diverged after 5 years. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This study supports the change in diagnostic category of the ESC/ERS guidelines in a PH population. The newly included patients have an increased mortality independent of significant lung or heart disease. The majority of patients in this new category have underlying heart or lung disease rather than an isolated pulmonary vasculopathy. Mortality is higher if comorbidity is present. Rigorous phenotyping will be pivotal to determine which patients are at risk of progressive vasculopathic disease and in whom surveillance and recruitment to studies may be of benefit. This study provides an insight into the population defined by the new guidelines.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37619574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37619574</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad532>10.1093/eurheartj/ehad532</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37619574</guid><pubDate> Thu, 24 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Nina Karia</dc:creator><dc:creator> Luke Howard</dc:creator><dc:creator> Martin Johnson</dc:creator><dc:creator> David G Kiely</dc:creator><dc:creator> James Lordan</dc:creator><dc:creator> Colm McCabe</dc:creator><dc:creator> Joanna Pepke-Zaba</dc:creator><dc:creator> Rose Ong</dc:creator><dc:creator> Michael Preiss</dc:creator><dc:creator> Daniel Knight</dc:creator><dc:creator> Vivek Muthurangu</dc:creator><dc:creator> J Gerry Coghlan</dc:creator><dc:date> 2023-08-24</dc:date><dc:source> European heart journal</dc:source><dc:title> Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study</dc:title><dc:identifier> pmid:37619574</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad532</dc:identifier></item><item><title> Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826020923&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 29;82(9):e77. doi: 10.1016/j.jacc.2023.06.018.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37612018/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37612018</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.06.018>10.1016/j.jacc.2023.06.018</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37612018</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Jaejin An</dc:creator><dc:creator> Yiyi Zhang</dc:creator><dc:creator> Andrew E Moran</dc:creator><dc:creator> Kristi Reynolds</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Reply: Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title><dc:identifier> pmid:37612018</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.018</dc:identifier></item><item><title> Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</title><link/> https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826020923&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 29;82(9):e75-e76. doi: 10.1016/j.jacc.2023.05.068.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37612017/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37612017</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.068>10.1016/j.jacc.2023.05.068</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37612017</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Michel Zeitouni</dc:creator><dc:creator> Johanne Silvain</dc:creator><dc:creator> Jean-Philippe Collet</dc:creator><dc:creator> Gilles Montalescot</dc:creator><dc:date> 2023-08-23</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Understanding Myocardial Infarction in Young Individuals Now or in 30 Years?</dc:title><dc:identifier> pmid:37612017</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.068</dc:identifier></item><item><title> Correction</title><link/> https://pubmed.ncbi.nlm.nih.gov/37612016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230826020923&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 29;82(9):969. doi: 10.1016/j.jacc.2023.07.010.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37612016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230826020923&v=2.17.9.post6+86293ac">37612016</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.07.010>10.1016/j.jacc.2023.07.010</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37612016</guid><pubDate> Wed, 23 Aug 2023 06:00:00 -0400</pubDate><dc:date> 2023-08-23</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Correction</dc:title><dc:identifier> pmid:37612016</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.010</dc:identifier></item></channel></rss>